Strs Ohio purchased a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 26,800 shares of the company's stock, valued at approximately $595,000.
Several other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the period. US Bancorp DE acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $33,000. Asset Management One Co. Ltd. acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $41,000. Wealthquest Corp acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $42,000. Finally, Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $61,000. 53.95% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Kiniksa Pharmaceuticals International news, insider Ross Moat sold 3,523 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total value of $124,397.13. Following the transaction, the insider directly owned 9,415 shares of the company's stock, valued at $332,443.65. This trade represents a 27.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $36.46, for a total transaction of $597,944.00. Following the sale, the chief operating officer directly owned 34,552 shares in the company, valued at approximately $1,259,765.92. The trade was a 32.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 561,371 shares of company stock valued at $18,825,009 over the last quarter. Insiders own 53.48% of the company's stock.
Kiniksa Pharmaceuticals International Trading Up 0.3%
Shares of KNSA traded up $0.10 during midday trading on Tuesday, hitting $36.18. 87,247 shares of the company's stock traded hands, compared to its average volume of 652,092. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $37.34. The firm's fifty day moving average is $32.77 and its 200-day moving average is $27.80. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of 904.73 and a beta of 0.20.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages recently commented on KNSA. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wells Fargo & Company increased their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 7th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $41.17.
Read Our Latest Research Report on KNSA
About Kiniksa Pharmaceuticals International
(
Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Read More

Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.
While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.